Die Opioidkrise in den USA: Ausmaß, Ursachen,
                    Gegenmaßnahmen und die europäische Situation im
                    Vergleich

Ulrich W. Preuss; Friedrich M. Wurst; Jessica Wei Mooi Wong

doi:10.1055/a-1153-3988

Suchttherapie, Table of Contents

Suchttherapie 2020; 21(02): 85-97
DOI: 10.1055/a-1153-3988

Schwerpunktthema

Die Opioidkrise in den USA: Ausmaß, Ursachen, Gegenmaßnahmen und die europäische Situation im Vergleich

The US Opioid Crisis: Extent, Causes, Counter-Measures and the European Situation in Comparison

Ulrich W. Preuss

¹Vitos Klinik Psychiatrie und Psychotherapie, Herborn und Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Martin-Luther-Universität, Halle-Wittenberg

,

Friedrich M. Wurst

²Psychiatrische Universitätsklinik Basel, Universität Basel, Schweiz

,

Jessica Wei Mooi Wong

³Klinik am Homberg, Bad Wildungen

› Author Affiliations

Abstract

Zusammenfassung

Der Opioid-Missbrauch und die Todesfälle durch Überdosierung haben in den USA krisenartige Ausmaße angenommen. Allein im Jahr 2017 starben mehr als 47 000 Amerikaner an einer Überdosis von Opioiden, und die Letalität ist auch in den Folgejahren auf einem hohen Niveau, da der Konsum synthetischer Opioide (z. B. Fentanyl-Derivate) in den letzten 5 Jahren erheblich zugenommen hat. Zur Bewältigung der Krise wurden mehrere Maßnahmen vorgeschlagen, darunter Programme zur Überwachung verschreibungspflichtiger Medikamente, Missbrauchs-verhindernde Opioid-Formulierungen, kognitive verhaltenstherapeutische und medikamentengestützte Ansätze und die Verteilung von Naloxon zur Behandlung von Opioid-Überdosierungen – mit bisher eher begrenztem Erfolg. Im Vergleich dazu gab es in mehreren Ländern Europas im letzten Jahrzehnt einen Anstieg der Verschreibungen von Opioiden. Die Letalität durch Opioide ist jedoch deutlich geringer als in den USA. Gründe für diese Unterschiede können auf unterschiedliche Zulassungen, Verschreibungsregeln (z. B. Deutsche Leitlinien zur LONTS, Update 2019) und bessere Implementierung von Qualitätsmaßnahmen zurückzuführen sein. In den USA erleichtert die Konzentration auf die medikamentöse Behandlung von Schmerzen anstatt der Therapie von psychosozialem Stress die Verschreibung von Opioiden. Außerdem ist MAT/OAT (medikamentös- oder opioidgestützte Substitutionstherapie) in vielen europäischen Ländern, insbesondere in ländlichen Gebieten, möglicherweise häufiger und umfassender verfügbar als in den USA.

Abstract

Opioid abuse and overdose deaths are at crisis levels in the USA. More than 47,000 Americans died of drug overdoses involving opioids in 2017 and lethality continues to stay on a high level, because synthetic opioid (e. g. fentanyl derivates) use has increased significantly during the last 5 years. Several measures have been proposed to tackle the crisis including prescription drug monitoring programs, abuse-deterrent opioid formulations, cognitive behavioral and medication-assisted therapies, and naloxone distribution to treat opioid overdose, with limited success. In comparison, several countries in Europe had an increase in opioid prescription during the last decade. However, lethality due to opioids is significantly lower than in the USA. Reasons for these differences may be due to different marketing permits, prescription rules (e. g. German Guidelines on LONTS long term opioid use in non-tumor pain, update 2019) and better results in quality measures. In the US focus on pain rather than treatment of psychosocial stress facilitate opiod prescription. Finally, MAT/OAT (medication or opioid assisted treatment) may be more frequently and comprehensively available in many European countries compared to the US, in particular in rural areas.

Schlüsselwörter

Opioid-Krise USA, - MAT (Medikamenten-Assistierte Therapie, - Substitutionstherapie), KVT (kognitive Verhaltenstherapie) Fentanylderivate - Drogenüberwachungsprogramme, Missbrauchs-abschreckende Opioid-Formulierungen - Naloxon - LONTS-Leitlinien

Key words

opioid crisis USA, MAT, CBT - fentanyl - Drug monitoring programs, abuse deterrent opioid formulations - Naloxone - LONTS guidelines

Full Text

References

Literatur
1 Volkow ND, Frieden TR, Hyde PS. et al. Medication-assisted therapies – tackling the opioid-overdose epidemic. N Engl J Med 2014; 370: 2063-2066
2 Muhuri PK, Gfroerer JC, Davies MC. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. 2013
3 European Monitoring Centre for Drugs and Drug Addiction EMCDDA Drug-related deaths and mortality in Europe Luxembourg: Publications Office of the European Union. 2019
4 Hedegaard H, Minino AM, Warner M. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief 329, National Center for Health Statistics, Hyattsville, MD. 2018
5 Ahmad FB, Rossen LM, Spencer MR. et al. Provisional drug overdose death counts, CDC National Center for Health Statistics. 2019
6 Florence CS, Zhou C, Luo F. et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care 2016; 54: 901-906
7 Dowell D, Haegerich TM, Chou R. Cdc guideline for prescribing opioids for chronic pain – United States, 2016. JAMA 2016; 315: 1624-1645
8 Chen Q, Larochelle MR, Weaver DT. et al. Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States. JAMA Netw Open 2019; 2: e187621
9 International Narcotics Control Board. Report of the International Narcotics Control Board for 2017. Retrieved from https://www. incb.org/incb/en/publications/annual-reports/annual-report-2017.html Vienna: United Nations; 2018
10 Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in Canada (January 2016 to June 2018), Public Health Agency of Canada, Ottawa 2018
11 United Nations Office on Drugs and Crime World Drug Report., United Nations publication, Sales No. E.17.XI.6). 2017
12 Theisen K, Jacobs B, Macleod L. et al. The United States opioid epidemic: a review of the surgeonʼs contribution to it and health policy initiatives. BJU Int 2018; 122: 754-759
13 Paulozzi LJ, Jones CM, Mack KA. et al. Vital signs: overdoses of prescription opioid pain relievers – United States, 1999–2008. MMWR Morb Mortal Wkly Rep Centers for Disease Control and Prevention 2011; 60: 1487-1492
14 Tick H, Nielsen A, Pelletier K. et al. The Pain Task Force of the Academic Consortium for Integrative Medicine and Health. Evidencebased Non-pharmacologic Strategies for Comprehensive Pain Care. A Consortium Pain Task Force White Paper. 2017
15 Häuser W, Wolfe F, Henningsen P. et al. Untying chronic pain: prevalence and societal burden of chronic pain stages in the general population – a cross-sectional survey. BMC Public Health 2014; 14: 352
16 Moulin DE, Clark AJ, Speechley M. et al. Chronic pain in Canada – prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag 2002; 7: 179-184
17 Benzon HT, Anderson TA. Themed Issue on the Opioid Epidemic: What Have We Learned? Where Do We Go From Here?. Anesth Analg 2017; 125: 1435-1437
18 Rudd RA, Seth P, David F. et al. Increases in drug and opioid-involved overdose deaths – United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016; 65: 1445-1452
19 Chihuri S, Li G. Trends in prescription opioids detected in fatally injured drivers in 6 US states: 1995–2015. Am J Public Health 2017; 107: 1487-1492
20 Rudisill TM, Zhu M, Kelley GA. et al. Medication use and the risk of motor vehicle collisions among licensed drivers: a systematic review. Accid Anal Prev 2016; 96: 255-270
21 Paulozzi LJ, Mack KA, Hockenberry JM. Variation among states in prescribing of opioid pain relievers and benzodiazepines – United States, 2012. J Safety Res 2014; 51: 125-129
22 Levy B, Paulozzi L, Mack KA. et al. Trends in opioid analgesic- prescribing rates by specialty, U.S., 2007–2012. Am J Prev Med 2015; 49: 409-413
23 Schoenfeld AJ, Jiang W, Chaudhary MA. et al. Sustained opioid use among previously opioid naïve patients insured through TRICARE (20016–2014). JAMA Surg 2017; 152: 1175-1176
24 Porter JH. Addication rare in patients treated with narcotics. J Engl J Med 1980; 302: 123
25 Alam A, Zheng H, Mamdani MM. et al. Long-term analgesic use after low risk surgery: a retrospective cohort study. Intern Med 2012; 172: 425-430
26 Brummett CM, Goesling J, Moser S. et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg 2017; 152: e170504
27 Goesling J, Zaidi B, Hassett AL. et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain 2016; 157: 1259-1265
28 Clarke H, Ko DT, Yun L. et al. Rates and risk factors for prolonged opioid use after major surgery: population based cohort study. BMJ 2014; 348: 1251
29 Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health 2009; 99: 221-227
30 Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of OxyContin^® and other opioid analgesics in the United States: 2002–2004. J Pain 2005; 6: 662-672
31 Hill MV, Stucke RS, Barth RJ. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. Ann Surg 2017; 265: 709-714
32 Bartels K, Dingmann C, Bullard KJ. et al. Opioid use and storage patterns by patients after hospital discharge following surgery. PLoS ONE 2016; 11: e0147972
33 Lipari R. How people obtain the prescription pain relievers they misuse. The CBHSQ Report: January 12, 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD. 2017
34 Kennedy-Hendricks A, McDonald E, McGinty EE. et al. Medication sharing, storage, and disposal practices for opioid medications among US adults. JAMA Intern Med 2016; 176: 1027-1029
35 Pollini RA, Cuevas-Mota J, Metzner M. et al. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abuse Rehabil 2011; 2: 173-180
36 Muhuri PK, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. CBHSQ Data Review, SAMHSA. 2013 Available at http://www.samhsa.gov/data/
37 Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med 2015; 373: 1789-1790
38 Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addict Behav. 2017; 74: 63-66
39 US Drug Enforcement Administration, Office of Diversion Control National Forensic Laboratory Information System Special Report: Opiates and related drugs reported in NFLIS, 2009–2014. Springfield, VA: US Drug Enforcement Administration. 2015
40 Rose ME. Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts. Pain Med. 2018; 19: 793-807
41 Gladden RM, Martinez P, Seth P. Fentanyl law enforcement submissions and increases in synthetic opioid–involved overdose deaths – 27 states, 2013–2014. MMWR Morb Mortal Wkly Rep 2016; 65: 837-843
42 Schuchat A, Houry D, Guy GP. New Data on Opioid Use and Prescribing in the United States. JAMA 2017; 318: 425-426 . doi: 10.1001/jama.2017.8913
43 Dowell D, Zhang K, Noonan RK. et al. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff (Millwood) 2016; 35: 1876-1883
44 Guy GP Jr, Zhang K, Bohm MK et al. Vital Signs: Changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017; 66: https://www.cdc.gov/mmwr/volumes/66/wr/mm6626a4.htm?s_cid=mm6626a4_w
45 Rudd RA, Seth P, David F. et al. Increases in drug and opioid-involved overdose deaths – United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016; 65: 1445-1452
46 Mercado MC, Sumner SA, Spelke MB. et al. Increase in drug overdose deaths involving fentanyl – Rhode Island, January 2012–March 2014. Pain Med. 2018 19. 511-523 doi: 10.1093/pm/pnx015
47 Clark T, Kreiner P, Strickler G. Prescription drug monitoring programs: an assessment of the evidence for best practices. Philadelphia (PA): Pew Charitable Trusts; 2012. . Available at http://www.pewtrusts.org/~/media/assets/0001/pdmp_update_1312013.pdf. Accessed February 2018
48 Nam YH, Shi Y, Moran JR. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care 2017; 23: 297-303
49 Brady JE, DiMaggio C, Lang BH. et al. Prescription drug monitoring and dispensing of prescription opioids. Public Health Rep 2014; 129: 139-147
50 Reifler LM, Bailey JE, Schnoll SH. et al. Do prescription monitoring programs impact state trends in opioid abuse/ misuse?. Pain Med 2012; 13: 434-442
51 Skolnick P. The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol 2018; 58: 143-159
52 Webster LR, Odinecs A, Herzog S. et al. 2012. Multiple dose pharmacokinetics and pharmacodynamics of the new oral opioid analgesic NKTR-181. Presented at Am. Acad. Pain Med., 28^th Annu.Meet., Palm Springs, CA, Pain Med. Poster 282B.
53 Jenkins T. 2016. Bio-activated opioid drugs with unprecedented oral and non-oral abuse-resistance. Presented at Am. Psychiat. Assoc. 169^th Annu. Meet., Atlanta, May 15, Symposium 4307. https://www.sbir.gov/sbirsearch/detail/1046491
54 Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012; 31: 207-225
55 Thomas CP, Fullerton CA, Kim M. et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv 2014; 65: 158-170
56 Rosenblatt RA, Andrilla CHA, Catlin M. et al. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. The Annals of Family Medicine 2015; 13: 23-26 . doi:10.1370/afm.1735
57 Qaseem A, Wilt TJ, McLean RM. et al. Clinical Guidelines Committee of the American College of Physicians Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2017; 166: 514-530
58 Bonakdar R, Palanker D, Sweeney MM. Analysis of State Insurance Coverage for Nonpharmacologic Treatment of Low Back Pain as Recommended by the American College of Physicians Guidelines. Glob Adv Health Med 2019; 8: 2164956119855629
59 Doleac JL, Mukherjee A. The Moral Hazard of Lifesaving Innovations: Naloxone Access, Opioid Abuse, and Crime, 2016. SSRN. Available at: https://ssrn.com/abstract=3135264 Accessed March 2018
60 Bosetti C, Santucci C, Radrezza S. et al. Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990–2016. Eur J Pain 2019; 23: 697-707
61 Berterame S, Erthal J, Thomas J. et al. Use of and barriers to access to opioid analgesics: A worldwide, regional, and national study. Lancet 2016; 387: 1644-1656
62 Hastie BA, Gilson AM, Maurer MA. et al. An examination of global and regional opioid consumption trends 1980–2011. Journal of Pain and Palliative Care Pharmacotherapy 2014; 28: 259-275
63 International Narcotics Control Board. Report of the International Narcotics Control Board for 2017. Retrieved from https://www.incb.org/incb/en/publications/annual-reports/annual-report-2017.html Vienna: United Nations; 2018
64 O'Brien T, Christrup LL, Drewes AM. et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain 2017; 21: 3-19
65 Knaul FM, Farmer PE, Krakauer EL. et al Lancet Commission on Palliative Care and Pain Relief Study Group Alleviating the access abyss in palliative care and pain relief – an imperative of universal health coverage: The Lancet Commission report. Lancet 2018; 391: 1391-1454
66 Chenaf C, Kaboré JL, Delorme J. Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality. Eur J Pain 2019; 23: 124-134
67 Just J, Mucke M, Bleckwenn M. Dependence on prescription opioids. Deutsches Arzteblatt International 2016; 113: 213-220
68 Werber A, Marschall U, L'Hoest H. et al. Opioid therapy in the treatment of chronic pain conditions in Germany. Pain Physician 2015; 18: E323-E331
69 Cherny NI, Baselga J, de Conno F. et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: A report from the ESMO/EAPC Opioid Policy Initiative. Annals of Oncology 2010; 21: 615-626
70 Vranken MJ, Lisman JA, Mantel-Teeuwisse AK. et al. Barriers to access to opioid medicines: A review of national legislation and regulations of 11 central and eastern European countries. Lancet Oncol 2016; 17: e13-e22
71 ONS (Office for National Statistics) (2018), Drug-related deaths ‘deep dive’ into coroners’ records: an experimental ‘deep dive’ study investigating deaths related to drug misuse in 2014 and 2015 using available coroners’ records https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/drugrelateddeathsdeepdiveintocoronersrecords/2018-08-06 2018
72 Pierce M, Millar T. Robertson Jr et al. Ageing opioid users’ increased risk of methadone-specific death in the UK. Int J Drug Policy 2018; 55: 121-127
73 Gao L, Dimitropoulou P. Robertson Jr et al. Risk-factors for methadone-specific deaths in Scotland’s methadone-prescription clients between 2009 and 2013. Drug Alcohol Depend 2016; 167: 214-223
74 Pierce M, Bird SM, Hickman M. et al. National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009. Drug Alcohol Depend 2015; 146: 17-23
75 Muller AE, Clausen T, Sjogren P. et al. Prescribed opioid analgesic use developments in three Nordic countries, 2006–2017. Scand J Pain 2019; 19: 345-353
76 Buth S, Holzbach R, Martens MS. et al. Problematic medication with benzodiazepine, “Z-drugs”, and opioid analgesics – an analysis of national health insurance prescription data from 2006–2016. Dtsch Ärztebl Int 2019; 116: 607-614
77 Häuser W, Bock F, Engeser P. et al. Clinical Practice guideline: long-term opioid use in non-cancer pain. Dtsch Ärztebl Inter 2014; 111: 732-740
78 Deutscher Schmerzgesellschaft e.V. S3-Leitlinie „LONTS“ – Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen. Update 2020. https://www.schmerzgesellschaft.de/topnavi/patienteninformationen/leitlinien-zur-schmerzbehandlung/lonts
79 White ND. Opioid abuse and overdose: prevention strategies. Am J Lifestyle Med 2015; 9: 412-415
80 Compton WM, Boyle M, Wargo E. Prescription opioid abuse: problems and responses. Prev Med 2015; 80: 5-9
81 Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the US: promises and perils. Pain 2013; 154: S94-S100
82 Häuser W, Petzke F, Radbruch L. et al. The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective. Pain Manag 2016; 6: 249-263
83 Müller-Schwefe G. Action program pain. Schmerz. Z Angew Schmerzth 1998; 4: 1
84 Nuckols TK, Anderson L, Popescu I. et al. Opioid prescribing: a systematic review and critical appraisal of guidelines forchronic pain. Ann Intern Med 2014; 160: 38-47
85 Cheung CW, Qiu Q, Choi SW. et al. Chronic opioid therapy for chronic noncancer pain: a review and comparison of treatment guidelines. Pain Physician 2014; 17: 401-414
86 Canada: National Opioid Use Guideline Group (NOUGG). Canadian guideline for safe and effective use of opioids for chronic noncancer pain (2010). http://nationalpaincentre.mcmaster.ca
87 Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980; 302: 123
88 World Health Organisation (WHO) Cancer pain relief, with a guide to opioid availability (1996), 2. edn. WHO; Geneva:
89 OCEBM (Oxford Center of Evidence Based Medicine) Levels of Evidence Working Group, The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o=5653 (2011), 2 edn. Oxford Centre for Evidence-Based Medicine, London